目标浓度干预：超越千禧年。
Target concentration intervention: beyond Y2K.
作者信息
Holford N H
机构信息
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.
出版信息
Br J Clin Pharmacol. 1999 Jul;48(1):9-13. doi: 10.1046/j.1365-2125.1999.00971.x.
Abstract
Target concentration intervention (TCI) is proposed as an alternative conceptual strategy to therapeutic drug monitoring (TDM). It is argued that the idea of a therapeutic range has limited the interpretation of measured drug concentrations and diminished the anticipated clinical benefit to patients by use of an oversimplified pharmacodynamic model. TCI on the other hand embraces pharmacokinetic and pharmacodynamic concepts and uses the idea of a target effect and associated target concentration to make rational individual dose decisions.
摘要
目标浓度干预（TCI）被提议作为治疗药物监测（TDM）的一种替代概念策略。有人认为，治疗范围的概念限制了对所测药物浓度的解释，并通过使用过于简化的药效学模型降低了对患者预期的临床益处。另一方面，TCI包含药代动力学和药效学概念，并利用目标效应和相关目标浓度的概念来做出合理的个体化剂量决策。
相似文献
1
Target concentration intervention: beyond Y2K.
Br J Clin Pharmacol. 1999 Jul;48(1):9-13. doi: 10.1046/j.1365-2125.1999.00971.x.
2
Target concentration intervention: beyond Y2K.
Br J Clin Pharmacol. 2001;52 Suppl 1(Suppl 1):55S-59S. doi: 10.1046/j.1365-2125.2001.0520s1055.x.
3
TDM is dead. Long live TCI!
Br J Clin Pharmacol. 2022 Feb;88(4):1406-1413. doi: 10.1111/bcp.14434. Epub 2020 Jul 1.
4
Best practice in therapeutic drug monitoring.
Br J Clin Pharmacol. 2001;52 Suppl 1(Suppl 1):5S-10S. doi: 10.1046/j.1365-2125.2001.0520s1005.x.
5
[Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].
Acta Clin Belg. 1999;53 Suppl 1:2-12.
6
Target concentration intervention in oncology: where are we at?
Ther Drug Monit. 2012 Jun;34(3):257-65. doi: 10.1097/FTD.0b013e3182557342.
7
Dose-response and concentration-response relationships: clinical and regulatory perspectives.
Ther Drug Monit. 1993 Dec;15(6):498-502. doi: 10.1097/00007691-199312000-00008.
8
[Therapeutic drug monitoring (TDM): definitions--vocabulary and concepts].
Therapie. 2001 May-Jun;56(3):239-43.
9
Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses.
J Pharmacokinet Pharmacodyn. 2005 Dec;32(5-6):703-18. doi: 10.1007/s10928-005-0083-6.
10
Best practice in therapeutic drug monitoring.
Br J Clin Pharmacol. 1998 Aug;46(2):95-9. doi: 10.1046/j.1365-2125.1998.00770.x.
引用本文的文献
1
Evaluation of the predictive performance of an online voriconazole dose calculator in children.
Eur J Clin Pharmacol. 2024 Dec;80(12):1989-1993. doi: 10.1007/s00228-024-03762-x. Epub 2024 Sep 26.
2
From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure.
Pharmaceutics. 2023 Mar 28;15(4):1081. doi: 10.3390/pharmaceutics15041081.
3
Artificial Intelligence and Machine Learning Approaches to Facilitate Therapeutic Drug Management and Model-Informed Precision Dosing.
Ther Drug Monit. 2023 Apr 1;45(2):143-150. doi: 10.1097/FTD.0000000000001078. Epub 2023 Feb 3.
4
On precision dosing of oral small molecule drugs in oncology.
Br J Clin Pharmacol. 2021 Feb;87(2):263-270. doi: 10.1111/bcp.14454. Epub 2020 Jul 17.
5
TDM is dead. Long live TCI!
Br J Clin Pharmacol. 2022 Feb;88(4):1406-1413. doi: 10.1111/bcp.14434. Epub 2020 Jul 1.
6
Pharmacodynamic principles and target concentration intervention.
Transl Clin Pharmacol. 2018 Dec;26(4):150-154. doi: 10.12793/tcp.2018.26.4.150. Epub 2018 Dec 19.
7
Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention.
Transplantation. 2019 Oct;103(10):2012-2030. doi: 10.1097/TP.0000000000002762.
8
A Fast Parameter Identification Framework for Personalized Pharmacokinetics.
Sci Rep. 2019 Oct 2;9(1):14143. doi: 10.1038/s41598-019-50810-z.
9
Predicting the dose of vancomycin in ICU patients receiving different types of RRT therapy: a model-based meta-analytic approach.
Br J Clin Pharmacol. 2019 Jun;85(6):1215-1226. doi: 10.1111/bcp.13904. Epub 2019 Apr 7.
10
Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data.
Br J Clin Pharmacol. 2019 Jun;85(6):1326-1336. doi: 10.1111/bcp.13901. Epub 2019 Apr 29.
本文引用的文献
1
Therapeutic drug monitoring of immunosuppressant drugs.
Br J Clin Pharmacol. 1999 Apr;47(4):339-50. doi: 10.1046/j.1365-2125.1999.00911.x.
2
The therapeutic monitoring of antimicrobial agents.
Br J Clin Pharmacol. 1999 Jan;47(1):23-30. doi: 10.1046/j.1365-2125.1999.00850.x.
3
Expanding clinical applications of population pharmacodynamic modelling.
Br J Clin Pharmacol. 1998 Oct;46(4):321-33. doi: 10.1046/j.1365-2125.1998.00792.x.
4
Therapeutic drug monitoring: antiarrhythmic drugs.
Br J Clin Pharmacol. 1998 Oct;46(4):307-19. doi: 10.1046/j.1365-2125.1998.t01-1-00768.x.
5
Therapeutic drug monitoring--antiepileptic drugs.
Br J Clin Pharmacol. 1998 Sep;46(3):185-93. doi: 10.1046/j.1365-2125.1998.00769.x.
6
Automated covariate model building within NONMEM.
Pharm Res. 1998 Sep;15(9):1463-8. doi: 10.1023/a:1011970125687.
7
Best practice in therapeutic drug monitoring.
Br J Clin Pharmacol. 1998 Aug;46(2):95-9. doi: 10.1046/j.1365-2125.1998.00770.x.
8
Therapeutic drug monitoring beyond 2000.
Br J Clin Pharmacol. 1998 Aug;46(2):93-4. doi: 10.1046/j.1365-2125.1998.00771.x.
9
Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.
Clin Pharmacokinet. 1998 Jan;34(1):57-77. doi: 10.2165/00003088-199834010-00003.
10
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.
N Engl J Med. 1998 Feb 19;338(8):499-505. doi: 10.1056/NEJM199802193380803.
Zotero 插件